drugset / Trial / NCT05183958
A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer
Phase 2
Unknown
118 enrolled
Zhejiang Cancer Hospital
Huizhou Municipal Central Hospital · collabJinhua Municipal Central Hospital · collabLishui Municipal Central Hospital · collabPeople's Hospital of Quzhou · collabSun Yat-Sen University Cancer Center · collabThe Affiliated People's Hospital of Ningbo University · collabThe First Affiliated Hospital of Wenzhou Medical Univercity · collabZhejiang Provincial People's Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A multi-center, open, randomized controlled, phase II clinical study to evaluate the efficiency and safety of chemotherapy and immunotherapy combined with locol radiotharepy in treatment of patients with oligometastatic esophageal carcinoma.
Timeline
- Start
- 2021-12-31
- Primary completion
- 2023-12-01
- Completion
- 2025-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Chemotherapy | Unknown | 200 mg/m2 | Intravenous |
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | Cisplatin | Other / unclassified | 50 mg/m2 | Intravenous |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Cisplatin | Other / unclassified | 80 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 800 mg/m2 | — |
| Subject | fluorouracil | Small molecule | 2000 mg/m2 | — |